Respiratorius AB (publ) (XSAT:RESP)

Market Cap	16.67M -32.2%
Revenue (ttm)	30.07K
Net Income	-6.65M
EPS	-0.91
Shares Out	7.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	2.120
Previous Close	2.220
Day's Range	2.110 - 2.120
52-Week Range	1.190 - 3.540
Beta	1.69
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About Respiratorius AB

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company’s products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 1
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: RESP

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 20, 2026

Data Sources Report a data error